Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Mitomycin 12Gemcitabine 9BCG Vaccine 4apaziquone 3Epirubicin 3erdafitinib 2durvalumab 2dodecyl maltoside 2VB4-845 2Docetaxel 2viscum album peptide 1valrubicin 1pirarubicin 1hydroxycamptothecinum 1Transurethral Resection of Bladder 1Therapeutic Uses 1Standard of Care 1Saline Solution 1Radiotherapy 1Polysorbates 1Maintenance 1Magnetic Resonance Spectroscopy 1Injections 1Cystoscopy 15-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Non-Muscle Invasive Bladder Neoplasms × valrubicin × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡